WHO Sanctions All Novartis Flu Vaccines for Developing World

20 December 2009 (Last Updated December 20th, 2009 18:30)

The World Health Organization (WHO) has granted prequalification for all three of Novartis' influenza A(H1N1) 2009 monovalent vaccines to be used in UN programmes across developing countries. The WHO has granted prequalification to the cell culture-based and MF59 adjuvanted vaccine Cel

The World Health Organization (WHO) has granted prequalification for all three of Novartis' influenza A(H1N1) 2009 monovalent vaccines to be used in UN programmes across developing countries.

The WHO has granted prequalification to the cell culture-based and MF59 adjuvanted vaccine Celtura, the egg-based MF59 adjuvanted vaccine Focetria and the egg-based A(H1N1) vaccine, which uses the seasonal Fluvirin platform.

Prequalification will facilitate adoption by UN agencies, which will enhance the pandemic vaccine that meet unified standards of quality and safety for developing countries.

The efficacy of the MF59 adjuvant was shown in randomised clinical trials and observational studies involving 124,000 individuals including children, adults and the elderly.

Celtura is an innovative adjuvanted, cell culture-based, inactivated subunit influenza vaccine indicated for active immunisation of those aged six months and older.

Focetria is an adjuvanted, egg-based, inactivated subunit influenza vaccine indicated for active immunisation of those aged six months and older against the novel pandemic A(H1N1) 2009 influenza virus.

Novartis Fluvirin platform A(H1N1) vaccine is an unadjuvanted, egg-based, inactivated subunit influenza vaccine indicated for active immunisation of those aged four years and older.